Breast cancer—The catalyst of contemporary trials design

Surgical trials in breast cancer have catalyzed contemporary trial design for solid organ cancers and are a prime example of surgeons taking the lead in clinical trial design. Surgeons have lead trials that have improved patient outcomes and quality of life without sacrificing oncologic safety. We have evolved from radical mastectomy to breast conservation and sentinel node biopsy. Contemporary trial design in breast cancer now focus on personalizing care based on tumor genomics

• Publication year

  2021

• Venue

  Journal of Surgical Oncology

• Publication date

  2021-12-13

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/jso.26722PMID 34897706
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Extrapolation of ACOSOG Z0011 trial results—A survey of breast cancer providers

  2021cited by this paper
• Pembrolizumab for Early Triple-Negative Breast Cancer.

  2020cited by this paper
• Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.

  2020cited by this paper
• Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy

  2020cited by this paper
• Avoiding Axillary Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy in Breast Cancer: Rationale for the Prospective, Multicentric EUBREAST-01 Trial

  2020influential reference
• Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study

  2020cited by this paper
• Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy

  2020cited by this paper
• Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer.

  2020cited by this paper
• Cosmetic Outcomes Following Breast-Conservation Surgery and Radiation for Multiple Ipsilateral Breast Cancer: Data from the Alliance Z11102 Study

  2020cited by this paper
• Cctg MA.39 tailor RT: A randomized trial of regional radiotherapy in biomarker low-risk node-positive breast cancer (NCT03488693).

  2019cited by this paper
• Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer

  2019cited by this paper
• Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?

  2018cited by this paper
• Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.

  2018cited by this paper
• De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

  2018cited by this paper
• Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy

  2018cited by this paper
• The Feasibility of Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial

  2018cited by this paper
• Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study

  2018cited by this paper
• Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer

  2018cited by this paper
• The Shifting Paradigm for Breast Cancer Surgery in Patients Undergoing Neoadjuvant Chemotherapy

  2017cited by this paper
• Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers: A Prospective Validation Study of 793 Patients

  2017influential reference
• Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.

  2017cited by this paper
• Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

  2017cited by this paper
• Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery

  2017cited by this paper
• Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

  2016cited by this paper
• How Often Is Treatment Effect Identified in Axillary Nodes with a Pathologic Complete Response After Neoadjuvant Chemotherapy?

  2016cited by this paper
• How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study

  2016cited by this paper
• Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy

  2016cited by this paper
• Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

  2015cited by this paper
• Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer.

  2015cited by this paper
• Increasing Use of Neoadjuvant Treatment for T1 and T2 HER2-Positive Tumors

  2015cited by this paper
• The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation

  2015cited by this paper
• Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.

  2015cited by this paper
• Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.

  2014cited by this paper
• Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

  2014cited by this paper
• Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.

  2013cited by this paper
• Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).

  2013cited by this paper
• Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.

  2013cited by this paper
• Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.

  2013cited by this paper
• Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

  2012cited by this paper
• Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

  2012cited by this paper
• The False-Negative Rate of Sentinel Node Biopsy in Patients with Breast Cancer: A Meta-Analysis

  2012cited by this paper
• Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

  2012cited by this paper
• Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.

  2012cited by this paper
• Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

  2012cited by this paper
• Adjuvant trastuzumab in HER2-positive breast cancer.

  2011cited by this paper
• Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.

  2011cited by this paper
• Multiple synchronous (multifocal and multicentric) breast cancer: clinical implications.

  2010cited by this paper
• Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: The American College of Surgeons Oncology Group Z0011 Randomized Trial

  2010cited by this paper
• Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.

  2010cited by this paper
• Conservative surgery in patients with multifocal/multicentric breast cancer

  2009cited by this paper
• Surgical Complications Associated With Sentinel Lymph Node Dissection (SLND) Plus Axillary Lymph Node Dissection Compared With SLND Alone in the American College of Surgeons Oncology Group Trial Z0011

  2009cited by this paper
• I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy

  2009cited by this paper
• Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.

  2009cited by this paper
• Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

  2008influential reference
• Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials.

  2008cited by this paper
• Breast Conservation Therapy (BCT) in Multifocal vs. Unifocal Early Stage Breast Cancer Patients: The Mayo Experience

  2007cited by this paper
• Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011.

  2007cited by this paper
• Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

  2006cited by this paper
• Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

  2006cited by this paper
• Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial

  2006cited by this paper
• [Breast cancer].

  2006cited by this paper
• Adjuvant trastuzumab for HER2-positive breast cancer.

  2005cited by this paper
• Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma

  2004cited by this paper
• Eighteen‐year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy

  2003cited by this paper
• The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

  2003cited by this paper
• Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial.

  2003cited by this paper
• Conservative surgery and radiation therapy for macroscopically multiple ipsilateral invasive breast cancers.

  2002cited by this paper
• Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.

  2002cited by this paper
• Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.

  2002influential reference
• Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.

  2002cited by this paper
• Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.

  2001cited by this paper
• Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.

  2001cited by this paper
• [Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial].

  2001cited by this paper
• Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.

  2001influential reference
• Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial.

  2000cited by this paper
• Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.

  1999cited by this paper
• Incidence and mortality from breast cancer in the mama program for breast screening in Finland, 1973–1986

  1994cited by this paper
• Should multicentric disease be an absolute contraindication to the use of breast-conserving therapy?

  1994cited by this paper
• Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer.

  1994cited by this paper
• Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer.

  1988cited by this paper
• A Randomized Prospective Trial of Radical (Halsted) Mastectomy Versus Modified Radical Mastectomy in 311 Breast Cancer Patients

  1983cited by this paper
• The primary surgical treatment of carcinoma of the breast: a changing trend toward modified radical mastectomy.

  1976cited by this paper

• No citing papers are available for this paper.